Clinical trial
Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's…
NCT00184080 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00184080 |
|---|---|
| Title | Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Multicenter Open-Label Non-Randomized Phase II Study of Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Lead sponsor | University of Southern California, Other |
| Collaborators | Spectrum Pharmaceuticals, Inc Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Elsamitrusin |
| Enrollment | 7 |
| Start date | May 1, 2004 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | May 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: